[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,586,798
  • Shares Outstanding, K 179,565
  • Annual Sales, $ 1,272 M
  • Annual Income, $ -245,030 K
  • EBIT $ -269 M
  • EBITDA $ -162 M
  • 60-Month Beta 3.62
  • Price/Sales 7.00
  • Price/Cash Flow N/A
  • Price/Book 21.36

Options Overview Details

View History
  • Implied Volatility 74.23% (-1.73%)
  • Historical Volatility 67.68%
  • IV Percentile 49%
  • IV Rank 39.40%
  • IV High 95.11% on 10/10/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 3) 3.07 (6.42%)
  • Put/Call Vol Ratio 0.41
  • Today's Volume 20,265
  • Volume Avg (30-Day) 32,119
  • Put/Call OI Ratio 0.53
  • Today's Open Interest 395,701
  • Open Int (30-Day) 352,818
  • Expected Range 44.75 to 50.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 4
  • High Estimate $-0.31
  • Low Estimate $-0.50
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) -13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.62 +12.20%
on 05/19/26
54.75 -12.66%
on 06/01/26
+0.87 (+1.85%)
since 05/12/26
3-Month
41.73 +14.59%
on 03/30/26
58.04 -17.61%
on 04/16/26
-1.71 (-3.45%)
since 03/12/26
52-Week
41.73 +14.59%
on 03/30/26
104.32 -54.16%
on 10/09/25
-23.41 (-32.87%)
since 06/12/25

Most Recent Stories

More News
Tempus Announces Multi-Center Validation of AI-Enabled ECG Model for Predicting Atrial Fibrillation Risk Published in Heart Rhythm

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced publication of successful multi-site validation of its software ...

TEM : 47.82 (-3.57%)
Genetics in Medicine Open Study Demonstrates How Ambry Genetics’ ExomeReveal® RNA Testing Can Improve Diagnostic Clarity in Exome Testing

Research highlights how ExomeReveal RNA analysis resolves ambiguity around uncertain variants to enable more genetic disease diagnoses

TEM : 47.82 (-3.57%)
Tempus to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that it will participate in the Goldman Sachs 47th Annual Global Healthcare...

TEM : 47.82 (-3.57%)
Tempus Launches Open-Source Digital Pathology Consortium, Names Yale New Haven Health and Leading Cancer Center as Founding Members

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, Yale New Haven Hospital (YNHH) and Memorial Sloan Kettering Cancer Center (MSK) today announced...

TEM : 47.82 (-3.57%)
Tempus Announces the Upcoming Clinical Availability of Its First Whole-Genome Sequencing Assay, xH

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the upcoming clinical availability of xH , a next-generation...

TEM : 47.82 (-3.57%)
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the launch of the next-generation of Lens, its pioneering agentic AI platform...

TEM : 47.82 (-3.57%)
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs...

TEM : 47.82 (-3.57%)
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically...

TEM : 47.82 (-3.57%)
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at...

TEM : 47.82 (-3.57%)
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a...

TEM : 47.82 (-3.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 52.35
2nd Resistance Point 51.17
1st Resistance Point 49.49
Last Price 47.82
1st Support Level 46.63
2nd Support Level 45.45
3rd Support Level 43.77

See More

52-Week High 104.32
Fibonacci 61.8% 80.41
Fibonacci 50% 73.03
Fibonacci 38.2% 65.64
Last Price 47.82
52-Week Low 41.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.